Post
Magazine: Anticipation rises for RSV rollout as positive data emerges
The last year was a momentous one for RSV research with more than one vaccine and a new treatment for …
Chinese companies lead ADC pipeline
Antibody drug conjugates (ADCs) are a rapidly growing therapeutic class that leading data and analytics company GlobalData forecasts will generate …
AstraZeneca admits Covid-19 vaccine may cause blood clots in “very rare” cases
AstraZeneca has been embroiled in a class action lawsuit for its Covid-19 vaccine, admitting that the vaccine may cause incidences …
Neurocrine bags FDA approval for new ‘sprinkle’ Ingrezza formulation
The US Food and Drug Administration (FDA) has approved an alternative formulation for Neurocrine Biosciences’ Huntington’s disease therapy, Ingrezza (valbenazine). The …
Janssen adopts J&J name as part of global rebranding effort
An iconic name in the pharma industry has vanished in the UK as Janssen – Johnson & Johnson’s (J&J) pharmaceutical …
Replay wins IND clearance for PRAME T cell cancer therapy
Genome writing company Replay Bio has had its investigational new drug (IND) application cleared by the US Food and Drug …
ePRO vs eCOA: Understanding the nuances in clinical trials
Two such tools – electronic patient-reported outcomes (ePRO) and electronic clinical outcomes assessments (eCOA) – are often mentioned together. However, …
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Last week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular endothelial growth factor (VEGF) and angiopoietin-2 …
Enlaza Therapeutics secures $100m in Series A funding
Enlaza Therapeutics has raised $100m in a Series A financing round headed by the Life Sciences group of JP Morgan …
Bayer and Evotec link to develop precision cardiology therapeutics
Bayer and German life science company Evotec have announced a strategic shift in their collaboration to focus on the development …
Eli Lilly reports 67% increase in Q1 2024 net income
Eli Lilly has announced that its net income on a reported basis rose to $2.24bn for the first quarter (Q1) …
Novartis and PeptiDream expand peptide discovery deal
Novartis and Japanese biopharmaceutical company PeptiDream have expanded their partnership for the discovery of peptides. Under the multi-programme deal, PeptiDream will …
ESCMID 2024: The infectious consequences of climate change
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, the …
Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
Pfizer and Genmab’s Tivdak (tisotumab vedotin-tftv) has won full approval from the US Food and Drug Administration (FDA) to treat …
Ionis Pharmaceuticals gets grant for modified oligonucleotide for reducing lRRK2 rna in neurodegenerative diseases
Ionis Pharmaceuticals has been granted a patent for compounds and methods to reduce LRRK2 RNA and protein levels in cells, …